Felbatol - felbamate Felbatol HomeFelbatol Home
About Felbatol
Patient Assistance Program
Prescribing Information
 

Patient Consent Form
Patient Consent Form Spanish
Email Site To Friend
Bookmark This Site
 










Meda Pharmaceuticals

Patient Assistance
Enrollment Instructions

Eligibility requirements
  • An annual household income of less than $16,000 for individuals and $25,000 for families
  • No prescription insurance (including Medicaid, Medicare, or any private assistance program)
Required documents
  • A completed and signed (by both patient and healthcare provider) application form
  • An original, signed prescription
  • A copy of the patient's tax return for the previous year, or completed IRS Tax Form 4506 (see instructions on application)
  • All other supporting documentation on income
  • All required documents should be sent to Meda Pharmaceuticals, Patient Assistance Program, 265 Davidson Avenue, Suite 300, Somerset, NJ 08873-4120
Prescription fulfillment/refill requirements
  • One 90-day supply of medication will be mailed directly to the healthcare provider
  • A separate application form and prescription are required each 90-day supply of medication
  • Income documentation is required only once a year
Contact Meda Pharmaceuticals for any questions regarding this program at 800-526-3840.


Privacy Policy     |     © Meda Pharmaceuticals Inc. - FEL6002   

Indications & Usage
Indications
  • FELBATOL (felbamate) should not be used as initial therapy in epilepsy (see Warnings in full Prescribing Information)
  • FELBATOL is recommended for use only in those patients who do not respond well to other treatments and whose epilepsy is so severe that the potential risk of developing aplastic anemia (a severe blood disorder) or liver failure is outweighed by the potential benefit of felbamate treatment.
  • After the patient or their caregiver has discussed the potential risks of Felbatol treatment with their doctor and have provided written consent, FELBATOL treatment can be considered. FELBATOL, by itself or in combination with other drugs is approved for the treatment of partial seizures, with or without generalization, in adults with epilepsy, and as combination therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
Additional Safety Information
  • FELBATOL should not be used in patients with a history of any blood or liver problems
  • Routine blood tests should be performed that can help identify potential blood or liver problems.
  • FELBATOL should be discontinued if there is evidence that blood or liver problems have occurred Adverse Events
  • The most common adverse experiences observed in clinical studies are loss of appetite, vomiting, insomnia, nausea, headache, and sleepiness